On Monday, Tempus AI got an upgrade to its Relative Strength (RS) Rating, from 62 to 82.
IBD's unique RS Rating tracks market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of above 80 as they launch their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buy zone in heavy trade.
Tempus AI showed 0% earnings growth in its most recent report. Revenue gains came in at 33%.
Tempus AI holds the No. 16 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
